Rubinstein, A., Mabudian, M., McNeil, D., Patel, N., Wasserman, R., Gupta, S., … Yel, L. (2023). Long-term safety of facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases: final analysis from a post-authorization safety study conducted in the USA. In Clinical Immunology (Vol. 250, pp. 109424–109424). Elsevier BV. https://doi.org/10.1016/j.clim.2023.109424

Rubinstein, Arye, Mohsen Mabudian, Donald McNeil, Niraj Patel, Richard Wasserman, Sudhir Gupta, Paz Carrasco, Andras Nagy, and Leman Yel. “Long-term safety of facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases: final analysis from a post-authorization safety study conducted in the USA.” In Clinical Immunology, 250:109424–109424. Elsevier BV, 2023. https://doi.org/10.1016/j.clim.2023.109424.

Rubinstein A, Mabudian M, McNeil D, Patel N, Wasserman R, Gupta S, et al. Long-term safety of facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases: final analysis from a post-authorization safety study conducted in the USA. In: Clinical Immunology. Elsevier BV; 2023. p. 109424–109424.

Rubinstein, Arye, et al. “Long-term safety of facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases: final analysis from a post-authorization safety study conducted in the USA.” Clinical Immunology, vol. 250, Elsevier BV, 2023, pp. 109424–109424. Crossref, doi:10.1016/j.clim.2023.109424.

Rubinstein A, Mabudian M, McNeil D, Patel N, Wasserman R, Gupta S, Carrasco P, Nagy A, Yel L. Long-term safety of facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases: final analysis from a post-authorization safety study conducted in the USA. Clinical Immunology. Elsevier BV; 2023. p. 109424–109424.